



Novel Targets of Drug Monitoring for Antibiotics

Guest Editor:

Prof. Dr. Yasuhiro Tsuji
Laboratory of Clinical
Pharmacometrics, Nihon
University, Chiba 274-8555,
Japan

Deadline for manuscript
submissions:
closed (15 April 2022)

Message from the Guest Editor

Drug monitoring is crucial to successfully curing patients' infections, as typified by vancomycin. Just over 20 years ago, target concentration intervention (TCI) was distinguished from therapeutic drug monitoring (TDM). Both TCI and TDM can be considered as approaches to concentration-controlled dosing of individual patients (Holford, 1999). Therapeutic drug monitoring (TDM) is a branch of clinical chemistry and clinical pharmacology that specializes in the measurement of medication concentrations in blood. On the other hand, target concentration intervention (TCI) embraces pharmacokinetic and pharmacodynamic concepts and uses the idea of a target effect and associated target concentration to make rational individual dose decisions. This Special Issue aims to publish high-quality manuscripts evaluating the novel target of drug monitoring for antibiotics. In the era of individualized medicine, further research of the safety and efficacy of drug monitoring of antibiotics based on novel targets (e.g., unbound drug concentration, metabolites and/or biomarkers) is warranted.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and
Molecular Bioscience, University
of Wollongong, Wollongong, NSW
2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

Contact Us

Antibiotics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
X@antibioticsmdpi